Pharma-Bio Serv, Inc. (PBSV) Form 10-Q — Sep 14, 2026
Pharma-Bio Serv filed its 10-Q for the quarter ended July 31, 2026, reporting revenues of $2.34 million, up roughly $0.4 million from a year earlier, with a near-breakeven net loss of $14,219 versus a $204,250 loss in the prior-year quarter. For the nine months, revenue rose to $7.33 million and the company swung to net income of $251,627 ($0.011 per share) from a $100,361 loss, helped by roughly $0.3 million of SG&A savings and growth in the Puerto Rico and Europe consulting segments.
Key figures
- Revenue
- 2336055
- Revenue Yoy
- up approximately $0.4 million for Q3 and $0.5 million for the nine months, per MD&A
- Total Assets
- 11439648
- Cash Position
- 1518314
- Shares Outstanding
- 22901692
- Sga Q3
- 763546
- Eps Nine Months
- 0.011
- Gross Profit Q3
- 691734
- Sga Nine Months
- 2337820
- Working Capital
- approximately $10.2 million
- Dividend Per Share
- 0.075
- Gross Margin Q3 Pct
- 29.6
- Total Liabilities
- 994740
- Revenue Nine Months
- 7333964
- Stockholders Equity
- 10444908
- Net Income Nine Months
- 251627
- Marketable Securities
- 7058837
- Dividend Paid Nine Months
- 1717627
- Romark Judgment Principal
- 5246782
- Allowance For Credit Losses
- approximately $5.3 million
- Gross Margin Nine Months Pct
- 31.6
- Shares Available For Repurchase
- 1444992
- Top Four Customer Concentration Q3 Pct
- 49.1
- Top Four Customer Concentration Nine Months Pct
- 52.6
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.